Several risk factors for the development of BMs have been identified, including younger age, specific ethnic backgrounds, tumor characteristics (such as poor differentiation, hormone receptor-negative status, and HER2-positive subtypes), the presence of more than four metastatic lymph nodes, and certain genetic variations [12,13]. This evidence concerns the gene ERBB2 and neoplasm.